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Background: Cathepsin D C224T polymorphism has been reported to associate with AD susceptibility. But the
results were inconsistent. This study aimed to assess the relationship between C224T polymorphism and AD risk.
Methods: The relevant studies were identified by searching PubMed, Embase, Web of Science, Google Scholar and
Wan fang electronic databases updated on July 2013. The relationship between Cathepsin D C224T polymorphism
and AD risk was evaluated by ORs and 95% CIs.
Results: A total of 25 case-control studies including 5,602 cases and 11,049 controls were included in the meta-
analysis. There was no association between C224T polymorphism and AD risk with all the studies were pooled in the
meta-analysis (CT vs. CC: OR = 1.125, 95% CI = 0.974-1.299, P = 0.109; CT + TT vs. CC: OR = 1.136, 95% CI = 0.978-1.320,
P = 0.094). Furthermore, when stratified by ethnicity, age of onset and APOEε4 status, significant association did not
found in all subgroups.
Conclusion: The present meta-analysis suggested that the Cathepsin D C224T polymorphism was not associated with
AD susceptibility.
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The neurodegenerative disorder Alzheimer’s disease (AD)
caused the most of dementia in the elderly [1]. Previous
findings indicated that the incidence increased from 1% in
65–69 year-olds to about 50% in 85–95 year-olds [2].
Many genetic and environmental risk factors contribute to
the degenerative progress of AD, such as family history,
low income and education, exposure to aluminium in
drinking water, dietary habits, smoking, physical activity,
hypertension, diabetes and genetic variations [3]. Molecu-
lar genetics researches have shown that AD was a class of
complex polygenic diseases with genetic heterogeneity.
Several genes have been reported to associate with AD.
Beta-amyloid precursor protein (APP) and presenilin 2
played major role in early-onset familial AD [4,5]. The
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reproduction in any medium, provided the orbinding cassette subfamily A member 7 (ABCA7) [7] have
been mainly implicated with late-onset AD. The ε4 allele
of apolipoprotein E (APOEε4) was the only verified risk
factor for sporadic AD [8]. However, the presence of var-
iants for these genes and the APOEε4 allele was neither
necessary nor sufficient for AD development. About 50%
of AD patients did not have mutations in the genes men-
tioned above or carry the APOEε4 allele, and not everyone
who has the mutations of the genes will acquire AD [9],
suggesting that it is necessary to identify additional
genetic or non-genetic factors which modulate the AD
susceptibility.
The main histopathologic features of AD are neuro-
fibrillary tangles and Neuritic plaques which consist of
hyperphosphorylated tau protein and amyloid peptides,
respectively. Cathepsin D (CTSD), an intracellular acid
protease, contributed to the proteolytic cleavage of APP
and the clearance of the β-amyloid (Aβ) from the central
nervous system [10,11]. As such, CTSD might involve in
the pathogenesis of AD. Variants of CTSD gene might. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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creasing the risk of AD. A CTSD C224T polymorphism
(C-to-T) in exon 2 can bring about amino acid change
(Ala38-to-Val), increase pro-CTSD secretion and alter
intracellular maturation [12]. It has been proved that this
polymorphism was significantly associated with the gen-
eral intelligence of healthy elderly [13].
Recently, numerous studies have focused on the cor-
relation between the CTSD C224T polymorphism and
AD risk [14-36]. Unfortunately, the results of these stud-
ies were contradictory. Five previous studies reported
that the T allele of the CTSD-C/T polymorphism was a
high-risk factor for developing AD [14-18]; however, other
relevant studies yielded contradictory results [19-36]. Fur-
thermore, the results of previous meta-analysis which re-
search the association between the CTSD polymorphism
and AD risk were contradictory as well. Bertram et al. [37]
and Ntais et al. [38] did not find any significant associa-
tion, whereas Schuur [18] reported that T allele increased
the risk of AD in Caucasians. Possible reasons for these
contradictory results include the small sample size of the
Ntais study; the absence of an Asian population in the
Schuur study; and the fact that the Bertram study only
compared alleles T and C. Considering that those factors
could contribute to bias in the final result, we updated the
present meta-analysis which included a larger sample size




The relevant studies were identified by searching PubMed,
Embase, Web of Science, Google Scholar and Wan fang
electronic databases in July 2013 for all the articles regard-
ing the correlation between CTSD C224T polymorphism
and AD risk. The key words of search strategy as follow:
“Alzheimer’s disease or AD”, “CTSD or cathepsin D”, and
“polymorphism, mutation or variant”. References listed in
reviews and retrieved articles were also screened. There
were no language or country restrictions. When multiple
articles researched the same cohort, the one with the
largest population was included. When a publication re-
ported more than one subpopulation, we regarded every
subpopulation as a separate study.
Selection criteria
The eligible studies were requested to agree with the in-
clusion criteria: (1) a case–control study; (2) research of
the correlation between CTSD C224T polymorphism and
AD susceptibility; (3)inclusion of the sample size and
distribution of alleles and genotypes; (4) AD diagnosed
according to the criteria of the National Institute of Neu-
rological and Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related Disorders Association(NINCDS-ADRDA), or the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV).
Exclusion criteria of our study were followed as: (1) dupli-
cated literature, reviews, or animal studies; (2) genotype
frequency and distribution were not included; (3) not
enough information for data extraction.
Data extraction
Two reviewers (Cuiju Mo and Jingzhe Sui) extracted the
information independently. If there was a disagreement,
the data was checked again, and a third reviewer (Xue
Qin) was invited to check the data. Information col-
lected from each eligible study was included: first author,
year of publication, country, ethnicity, genotyping me-
thod, AD diagnosis, control sources, sample sizes, age of
onset, and genotype distribution in cases and controls.
Statistical analysis
All analysis was conducted using Stata version 12.0 soft-
ware (Stata Corp, College Station, TX). The association
was assessed by pooled odds ratio (OR) together with
the corresponding 95% confidence interval (CI). Only
heterozygote comparison model (TC vs. CC) and the
dominant genetic model (TT + TC vs. CC) were analysed.
Furthermore, we evaluated the effect in different sub-
group stratified by ethnicity (Asian vs. Caucasian) and
age of onset. Early-onset AD (EOAD) was defined as age
at onset <65 years, and age at onset ≥65 years was consid-
ered as late-onset AD (LOAD). To evaluate the interac-
tion of the CTSD with the APOEε4 allele, we compared
the dominant genetic model (TT +TC vs. CC) between
case and control subjects stratified by the APOEε4 allele
status. Similarly, the relationship of the APOEε4 allele with
AD risk was investigated between the patients carrying
the T allele or not.
The x2-test based Q-statistic and I2 statistic was used
to evaluate the heterogeneity among the studies. The
DerSimonian–Laird random-effects model was used to
assess pooled OR when a significant heterogeneity (PQ <
0.1 or I2 ≥ 50%) was observed. Otherwise, the Mantel–
Haenszel fixed-effects model was used. The publication
bias was detected by funnel plot and Egger’s test. An
Egger’s test P value <0.05 was considered as statistically
significant. The genotype distribution of the control popu-
lation was used to evaluate Hardy–Weinberg Equilibrium
(HWE) by a goodness-of-fit Chi-square test. P <0.05 (two-
side) was considered as statistically significant.
Results
Eligible studies
Figure 1 showed the screening process of our study. A
total of 345 articles were identified from the database
searching and references of review. 31 relevant articles
were identified according to inclusion criteria. Then eight
Figure 1 Flow chart of literature screening for this meta-analysis.
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was a meta-analysis [38], two articles did not provide suffi-
cient data [39,40], and five articles overlapped with other
published studies [32,41-44]. Finally, 23 articles including
22 English papers and 1 Chinese paper [19] were included
in our study. Two out of the including articles reported
two subpopulations, and each subpopulation was con-
sidered as a separate study. Therefore, 25 case–control
studies including 5,602 cases and 11,049 controls were in-
cluded in the meta-analysis, encompassing 4 Asian and 21
Caucasian samples. All AD patients were diagnosed by
NINCDS-ADRDA criteria, DSM-IV criteria, or autopsy
confirmation in all eligible studies. The genotype frequen-
cies of the control groups in two case–control studies
deviated from the HWE [22,29]. Ten of the eligible
studies evaluated the interaction between the CTSD
and the APOEε4 allele [1,14,15,18-21,24,28,29,34]. Six
of the studies included early-onset and late-onset cases
[20,21,28,29,33,34]. The baseline data of each case–control
study were presented in Table 1.
Results of meta-analysis
The present finding of this meta-analysis revealed that
the C224T polymorphism was not associated with AD
risk. The heterogeneities of CT vs. CC and the dominant
CT + TT vs. CC models were assessed in the overall
population, and the PQ values were 0.023 and 0.007,
respectively. Thus, random-effects model was chose to
analyse the CT vs. CC model (OR = 1.125, 95% CI =
0.974–1.299, P = 0.109, Table 2, Figure 2A) and the
dominant CT + TT vs. CC model (OR = 1.136, 95% CI =
0.978–1.320, P = 0.094, Table 2, Figure 2B) in the overallpopulation. The control genotypes of two case-control
studies [22,29] deviated from the HWE. The summary
ORs were slightly elevated in the CT vs. CC (OR =
1.127, 95% CI = 0.965-1.317, P = 0.132) and dominant
CT + TT vs. CC models (OR = 1.149, 95% CI = 0.978-1.35,
P = 0.09) without a statistical significance, when we ex-
cluded those two studies.
In subgroup analyses stratified by ethnicity, we failed
to find any significant associations between the CTSD
C224T polymorphism and AD risk in the Asian (CT vs.
CC: OR = 0.971, 95% CI = 0.626-1.506, P = 0.895; CT +
TT vs. CC: OR = 0.954, 95% CI = 0.616-1.477, P = 0.833,
Table 2) and Caucasian(CT vs. CC: OR = 1.139, 95% CI =
0.974-1.331, P = 0.102; CT + TT vs. CC: OR = 1.154, 95%
CI = 0.982-1.357, P = 0.082, Table 2) populations. After ex-
cluding two studies [22,29] which deviated from the HWE,
no significant associations were found between the CTSD
C224T polymorphism and AD risk in the Asian (CT +TT
vs. CC: OR = 0.968, 95% CI =0.605-1.548, P = 0.891) and
Caucasian(CT +TT vs. CC: OR = 1.165, 95% CI =0.981-
1.383, P = 0.081). Similarly, we found non-significant asso-
ciations in the EOAD (CT vs. CC: OR = 0.937, 95% CI =
0.706-1.245, P = 0.654; CT +TT vs. CC: OR = 0.930, 95%
CI = 0.704-1.229, P = 0.612) and LOAD (CT vs. CC: OR =
0.935, 95% CI = 0.724-1.207, P = 0.606; CT +TT vs. CC:
OR = 0.931, 95% CI = 0.726-1.195, P = 0.575)subgroups in
any of the comparisons (Table 2).
In the APOEε4 stratified analyses, the results did not
show significant associations between the C224T poly-
morphism and AD risk in APOEε4 carriers and non-
carriers. However, the pooled OR were higher in APOEε4
carriers (CT +TT vs. CC: OR = 1.267, 95% CI = 0.979-1.641,
Table 1 The baseline data of all including study







Sun 2005 China Asian PCR-RFLP NINCDS-ADRDA and
DSM-IV
PB 0.552 165 174
Li 2004 China Asian PCR-RFLP NINCDS-ADRDA PB 0.484 156(42/114) 183
Jhoo 2005 Korea Asian DASH NINCDS-ADRDA PB 0.701 107(36/71) 216
Matsui 2001 Japan Asian PCR-RFLP NINCDS-ADRDA PB 0.000 275 479
USA Caucasian PCR-RFLP autopsy-confirmed PB 0.191 69 50
Papassotiropoulos 1999 Germany Caucasian PCR-RFLP NINCDS-ADRDA PB 0.21 102 351
McIlroy 1999 Ireland Caucasian PCR-RFLP DSM IV and
NINCDS-ADRDA
PB 0.367 183 187
Papassotiropoulos 2000(b) Germany Caucasian PCR-RFLP NINCDS-ADRDA HB 0.485 127 184
Bhojak 2000 USA Caucasian PCR-RFLP NINCDS-ADRDA HB 0.084 531 316
Crawford 2000 USA Caucasian PCR-RFLP NINCDS-ADRDA HB 0.319 210 120
Spain Caucasian PCR-RFLP NINCDS-ADRDA HB 0.101 79 112
Menzer 2001 Germany,
Switzerland, Italy
Caucasian PCR-RFLP NINCDS-ADRDA HB and PB 0.988 324 302
Bertram 2001 USA Caucasian PCR-RFLP NINCDS-ADRDA HB 0.373 200 182
Emahazion 2001 Scotland Caucasian DASH DSM-IV Not clarified. 0.329 120 149
Bagnoli 2002 Italy Caucasian PCR-RFLP DSM-IV PB 0.616 197(33/33) 126
Mateo 2002 Spain Caucasian PCR-RFLP NINCDS-ADRDA HB 0.008 311(126/185) 346
Styczynska 2003 Polish Caucasian PCR-RFLP NINCDS-ADRDA HB 0.637 100 100
Ingegni 2003 Italy Caucasian PCR-RFLP NINCDS-ADRDA HB 0.914 142 120
Beryer 2005 Spain Caucasian PCR-RFLP DSM-IV and
NINCDS-ADRDA
Not clarified. 0.871 205 181
Blomqvist2 2006 Switzerland Caucasian DASH NINCDS-ADRDA HB and PB 0.372 385 173
Mariani 2006 Italy Caucasian PCR-RFLP NINCDS-ADRDA PB 0.355 100 136
Davidson 2006 UK Caucasian PCR-RFLP NINCDS-ADRDA HB 0.168 560(317/243) 767
Capurso 2008 Italy Caucasian PCR-RFLP NINCDS-ADRDA PB 0.205 242(57/185) 421
Albayrak 2010 Germany Caucasian PCR-RFLP NINCDS-ADRDA HB 0.143 219 215
M. Schuur 2011 Netherland Caucasian Taqman assay NINCDS-ADRDA PB 0.631 493 5619
PCR–RFLP, Polymerase chain reaction-restriction fragment length polymorphism; DASH, dynamic allele specific hybridization; PB, Population–based; HB, Hospital–based;
HWE, hardy-Weinberg equilibrium; EOAD, early-onset AD; LOAD, late-onset AD.
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OR = 1.139, 95% CI = 0.844-1.539, P = 0.395, Table 3). Fur-
thermore, among the T allele carriers, APOEε4 allele in-
creased the risk of AD 4.5-fold (OR = 4.532, 95% CI =
2.755-7.455, P = 0.000, Table 3) accompanied by hetero-
geneity (P = 0.033). Among the subjects without the T al-
lele, APOEε4 increased the risk of AD 4.2-fold (OR =
4.193, 95% CI =3.096-5.679, P = 0.000, Table 3) with sig-
nificant between-study heterogeneity (P = 0.000). Exten-
sive overlap existed between the two estimates; however,
the ORs were greater in the T allele carriers.
Publication bias
There was no visible publication bias among the studies
because of the shape of the Begg’s funnel plots re-
vealed symmetry in the CT vs. CC and CT +TT vs. CCcomparative genetic models (Figure 3). Statistical evidence
of funnel plot symmetry was provided by Egger’s test. The
results also showed no publication bias in the C224T po-
lymorphism (t = -0.19, P = 0.853 for CT vs. CC; t = -0.34,
P = 0.736 for CT +TT vs. CC).
Discussion
The effects of genetic sequence variants in complex hu-
man traits are not readily detectable in population sam-
ples. However, meta-analysis that accumulates published
data from small single research is a valuable tool in
identifying disease genes. The functions of CTSD are to
hydrolyse APP protein and clear Aβ from the central
nervous system [10,11]. In AD patients, CTSD was ex-
pressed in the core of neuritic plaques [45], and cellular
and cerebrospinal levels are elevated [46]. The variants
Table 2 Results of the association between CTSD C224T polymorphism and AD risk in the meta-analysis
Comparison Population No. of studies Test of association Mode Test of heterogeneity
OR 95% CI P Value x2 PQ Value I
2
CT vs. CC Overall 25 1.125 0.974–1.299 0.109 R 39.65 0.023 39.5
CT + TT vs. CC Overall 25 1.136 0.978–1.320 0.094 R 44.23 0.007 45.7
Subgroup analysis
Ethnicity
CT vs. CC Asian 4 0.971 0.626–1.506 0.895 F 2.04 0.565 0.0
Caucasian 21 1.139 0.974–1.331 0.102 R 37.20 0.011 46.2
CT + TT vs. CC Asian 4 0.954 0.616–1.477 0.833 F 2.04 0.565 0.0
Caucasian 21 1.154 0.982–1.357 0.082 R 41.54 0.003 51.8
EOAD
CT vs. CC Overall 6 0.937 0.706–1.245 0.654 F 2.87 0.719 0.0
CT + TT vs. CC Overall 6 0.93 0.704–1.229 0.612 F 2.68 0.749 0.0
LOAD
CT vs. CC Overall 6 0.935 0.724–1.207 0.606 F 3.86 0.57 0.0
CT + TT vs. CC Overall 6 0.931 0.726–1.195 0.575 F 3.88 0.567 0.0
OR, odds ratio; CI, confidence intervals; R, random effects model; F, fixed effects model; EOAD, early-onset AD; LOAD ,late-onset AD.
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APP and the degradation and clearance of Aβ, the syn-
thesis of which is a supposed pivotal event in the patho-
genesis of AD. Therefore, our motivation for the present
study was to determine the association between CTSD
polymorphism and AD risk from abundant data over
16,651 genotype cases and controls.
As far as we know, the present meta-analysis involving
5602 cases and 11,049 healthy controls was the most com-
prehensive to date to investigate the relation between the
CTSD C224T polymorphism and AD susceptibility. Our
finding indicated that the C224T polymorphism was notFigure 2 Forest plots of CTSD C224T polymorphism and AD risk (A, C
random-effect model.associated with the AD risk both in Asian and Caucasian
populations, which were in accord with the results of the
previous meta-analysis [38] and inconsistent with Schuur’s
results [18]. Compared to the previous study, our meta-
analysis has some particular strength. First, we had the lar-
gest sample size; we added four Asian population studies,
the absence of which in the Schuur study might have
caused a deviation in the final result; and ten new case–
control studies were added compared to the Ntais study,
which might have effectively altered the overall results.
Second, because nearly half of the eligible studies did
not detect the homozygous TT polymorphism, and theT vs. CC model; B, TT + CT vs. CC model) in all analysis using
Table 3 Meta-analysis the association of CTSD C224T polymorphism with APOEε4 carrier in AD
Comparison Population No. of studies Test of association Mode Test of heterogeneity
OR 95% CI P Value x2 PQ Value I2
APOEε4 noncarriers
CT + TT vs. CC Overall 10 1.139 0.844–1.539 0.395 R 19.28 0.023 53.3
Asian 3 0.73 0.390–1.365 0.324 F 5.81 0.055 65.5
Caucasian 7 1.212 0.998–1.472 0.052 F 11.86 0.065 49.4
APOEε4 carriers
CT + TT vs. CC Overall 10 1.267 0.979–1.641 0.072 F 10.89 0.283 17.4
Asian 3 1.273 0.511–3.184 0.604 F 0.01 0.995 0.0
T carriers Caucasian 7 1.267 0.979–1.641 0.085 F 10.88 0.092 44.9
APOEε4(+) vs. APOEε4(–) Overall 10 4.532 2.755–7.455 0.000 R 18.16 0.033 50.4
Asian 3 7.913 2.632–23.785 0.000 F 0.20 0.904 0.0
Caucasian 7 4.134 2.338–7.310 0.000 R 15.58 0.016 61.5
T noncarriers
APOEε4(+) vs. APOEε4(–) Overall 10 4.193 3.096–5.679 0.000 R 43.54 0.000 79.3
Asian 3 4.217 2.333–7.620 0.000 R 6.88 0.032 70.9
Caucasian 7 4.195 2.888–6.093 0.000 R 35.89 0.000 83.3
OR, odds ratio; CI, confidence intervals; R, random effects model; F, fixed effects model.
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polymorphisms, heterozygote might be responsible for the
significant difference in frequency; therefore, we only
compared the CT vs. CC and the dominant CT +TT vs.
CC models. Lastly, no significant publication bias was ob-
served in any of the studies analyzing by Egger’s test and
Begg’s funnel plot. Thus, based on the above factors, the
results of our meta-analysis were more reliable than those
of previous studies.
Our results from the CT vs. CC and dominant CT +
TT vs. CC comparison models suggested that no signifi-
cant correlation was existed between the CTSD C224T
polymorphism and AD risk. Given that the control ge-
notypes of two case-control studies [22,29] were out ofFigure 3 Funnel plot for publication bias of all eligible studies (A, CTHWE, they might have contributed some bias to our
summary OR. When we excluded those two studies, the
summary OR was not effectively altered, showing that
our result was reliable. A great degree of heterogeneity
among studies was identified for CT vs. CC (x2 = 39.65,
PQ = 0.023) and CT + TT vs. CC (x
2 = 44.23, PQ = 0.007)
in the overall populations. Several factors might con-
tribute to the heterogeneity. First, AD is a complicated
and multi-genetic disease. Second, clinical heterogeneity,
such as gender, age of onset, and diagnosis criteria, were
factors. The different studied populations, such as ethni-
city, might also explain the discrepancy. In subgroup
analysis stratified by ethnicity and age of onset, heteroge-
neity only existed in the Caucasian subgroup, indicatingvs. CC; B, CT + TT vs. CC).
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heterogeneity.
Considering the impact on the summary OR of diffe-
rent ethnicities, we further performed subgroup analysis
based on ethnicity. Those results indicated no significant
association between the CTSD C224T polymorphism
and AD risk either in Asian or in Caucasian population,
which was inconsistent with the previous meta-analysis
[18]. Similarly, the results did not change when the two
studies that violated HWE [22,29] were excluded. The
number of samples in the Asian subgroup was dramatic-
ally less than those in the Caucasian subgroup, which
may weaken the conclusions. Our results also differed
from the Schurr study after excluding the Mateo study
in Caucasian population. While after excluding Albayrak
[39] and Mateo [33] study, a significant association was
found in the dominant CT + TT vs. CC genetic model
(OR = 1.201, 95% CI = 1.004-1.436, P = 0.045). The prin-
cipal cause for the difference with our results was the
inclusion of the Albayrak [39] study. The Albayrak study
reported that the CTSD C224T polymorphism increased
AD risk in men only which might cause the false-negative
result. As no study has clarified gender-specific differences
regarding lysosomes or its components and the character-
istic lesions in AD, therefore, future study with larger sam-
ples to investigate the gender-specific is necessary. When
stratified by age of onset, we found no significant differ-
ences both in EOAD and LOAD subsets. Possible expla-
nations for these findings might be the small sample sizes
for analysis; the same control source, without strict age
matching, and missing age information in some studies.
Given these factors may affect the statistical power. Fur-
ther research is required to assess the gene effects and
validate our findings.
To evaluate the interaction of CTSD polymorphism
and APOEε4 allele on AD, ten studies which provided
genotype distribution data of APOEε4 status were cho-
sen for further study, and of which only four showed
evidence of an association [14,15,20,25]. The results of
our study showed non-significant relation between the
C224T polymorphism and AD risk in APOEε4 carriers
and non-carriers. The association of CTSD T allele with
AD risk between APOEε4 carriers and non-carriers in
Caucasians was quite similar, contrary to the Schuur
result. Due to the lack of an Asian population in the
Schuur study, sample size and ethnicity might have
contributed to some bias in the final result. While the
ORs of APOEε4 were greater in the T allele carriers
group than the subjects without the T allele. Because
of the extensive overlap in two effect sizes and the re-
markably small group of subjects who carry both the
APOEε4 and CTSD T alleles, the association between
the CTSD T and APOEε4 alleles should be interpreted
cautiously.There were some limitations that merit attention.
First, some of the eligible studies lacked sufficient infor-
mation for detailed and deep analysis. In some studies,
the controls were not uniformly defined as matched
by age and gender; and it may lead to some negative
correlation. Second, we mainly focused on the C224T
polymorphism, discounted the potential linkage dis-
equilibrium with another mutation of this gene, and
ignored the interactions between gene and gene or
gene and environment. Third, the data of our meta-
analysis was unadjusted; the suspected factors could
be analysed, such as, gender, diet, lifestyle habit, and
environmental factors. Fourth, we included the English or
Chinese publications only; the lack of unpublished data
and data published in other languages might contribute
some bias. There were only four articles in the Asian sub-
group, with small sample size, which may cause low statis-
tical power.
Conclusions
The finding of our present study revealed that the CTSD
C224T polymorphism was not associated with AD risk
both in the overall populations and the subgroups strati-
fied by ethnicity and age of onset. In addition, we found
no statistically significant differences between the CTSD
C224T genotypes and AD stratified by APOEε4 allele
status. Our data did not suggest that the CTSD C224T
polymorphism was a possible susceptibility factor for AD.
Future studies will require much larger sample sizes and
will need to analyse the impact of this polymorphism in
other populations.
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